Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 33.33% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Entera Bio Ltd. (ENTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Entera Bio Ltd. (ENTX) delivered earnings and revenue surprises of 16.67% and 86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
In the absence of a marketed product, Entera Bio (ENTX) is expected to provide an update on its pipeline candidates, mainly EB613 and EB612, for the treatment of osteoporosis and hypoparathyroidism, respectively....
Entera Bio Ltd. (ENTX) closed the most recent trading day at $0.91, moving +1.11% from the previous trading session.
Entera Bio Ltd. (ENTX) closed at $0.95 in the latest trading session, marking no change from the prior day.
Entera Bio Ltd. (ENTX) closed at $0.90 in the latest trading session, marking a -1% move from the prior day.
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.95, marking no change from the previous day.
In the latest trading session, Entera Bio Ltd. (ENTX) closed at $0.88, marking a +1.87% move from the previous day.